Ferrocenyl hydroxymethylphosphines (η⁵-C₅H₅)Fe[η⁵⁻C₅H₄P(CH₂OH)₂] and 1,1′-[Fe{η⁵-C₅H₄P(CH₂OH)₂}₂] and their chalcogenide derivatives

The ferrocenyl hydroxymethylphosphines FcP(CH₂OH)₂ [Fc=(η⁵-C₅H₅)Fe(η⁵-C₅H₄)] and 1,1′-Fc′[P(CH₂OH)₂]₂ [Fc′=Fe(η⁵⁻C₅H₄)₂] were prepared by reactions of the corresponding primary phosphines FcPH₂ and 1,1′-Fc′(PH₂)₂ with excess aqueous formaldehyde. The crystal structure of FcP(CH₂OH)₂ was determined and compared with the known ferrocenyl hydroxymethylphosphine FcCH₂P(CH₂OH)₂. The chalcogenide derivatives FcP(E)(CH₂OH)₂ and 1,1′-Fc′[P(E)(CH₂OH)₂]₂ (E=O, S, Se) were prepared and fully characterised. Crystal structure determinations on FcP(O)(CH₂OH)₂ and FcP(S)(CH₂OH)₂ were performed, and the hydrogen-bonding patterns are compared with related compounds. The sulfide shows no hydrogen-bonding involving the phosphine sulfide group, in contrast to other reported ferrocenyl hydroxymethylphosphine sulfides. The platinum complex cis-[PtCl₂{FcP(CH₂OH)₂}₂] was prepared by reaction of 2 mol equivalents of FcP(CH₂OH)₂ with [PtCl₂(1,5-cyclo-octadiene)], and was characterised by 31P-NMR spectroscopy and negative ion electrospray mass spectrometry, which gave a strong [M+Cl]⁻ ion

Platinum(II) complexes containing ferrocene-derived phosphonate ligands; synthesis, structural characterisation and antitumour activity

Platinum ferrocenyl–phosphonate complexes, containing four-membered Pt---O---P(O)---O rings, have been synthesised by the reactions of cis-[PtCl₂(PPh₃)₂] with the ferrocene-derived phosphonic acids Fc(CH₂)nP(O)(OH)₂(n=0–2) [Fc=(η⁵-C₅H₄)Fe(η⁵-C₅H₅)] and 1,1′-Fc′[P(O)(OH)₂]₂ [Fc′=Fe(η⁵-C₅H₄)₂] in the presence of Ag₂O. The complexes have been characterised by NMR spectroscopy, together with crystal structure determinations on [Fc(CH₂)nPO₃Pt(PPh₃)₂] (n=1, 2) and [1,1′-Fc′{PO₃Pt(PPh₃)₂}₂]. The complexes [Fc(CH₂)nPO₃Pt(PPh₃)₂] (n=1, 2) show moderate activity against P388 leukaemia cells, whereas the parent phosphonic acids are inactive

‘User-friendly’ primary phosphines and an arsine: synthesis and characterization of new air-stable ligands incorporating the ferrocenyl group

Reaction of FcCH₂CH₂P(O)(OH)₂ or FcCH₂P(O)(OH)(OEt) [Fc=Fe(η⁵-C₅H₄)(η⁵-C₅H₅)] with excess CH₂N₂ followed by reduction with Me₃SiCl–LiAlH₄ gives the air-stable primary phosphines FcCH₂CH₂PH₂ and the previously reported analogue FcCH₂PH₂ in high yields. Reduction of 1,1′-Fc′[CH₂P(O)(OEt)₂] [Fc′=Fe(η⁵-C₅H₄)₂] and 1,2-Fc″[CH₂P(O)(OEt)₂] [Fc″=Fe(η⁵-C₅H₅)(η⁵-C₅H₃)] similarly gives the new primary phosphines 1,1′-Fc′(CH₂PH₂)₂ and 1,2-Fc″(CH₂PH₂)₂, respectively. The arsine FcCH₂CH₂AsH₂, which is also air-stable, has been prepared by reduction of the arsonic acid FcCH₂CH₂As(O)(OH)₂ using Zn/HCl. An X-ray structure has been carried out on the arsine, which is only the second structure determination of a free primary arsine. The molybdenum carbonyl complex [1,2-Fc″(CH₂PH₂)₂Mo(CO)₄] was prepared by reaction of the phosphine with [Mo(CO)₄(pip)₂] (pip=piperidine), and characterized by a preliminary X-ray structure determination. However, the same reaction of 1,1′-Fc′(CH₂PH₂)₂with [Mo(CO)₄(pip)₂] gave [1,1′-Fc′(CH₂PH₂)₂Mo(CO)₄] and the dimer [1,1′-Fc′(CH₂PH₂)₂Mo(CO)₄]₂, characterized by electrospray mass spectrometry. 1,1′-Fc′[CH₂PH₂Mo(CO)₅]₂ and 1,2-Fc″[CH₂PH₂Mo(CO)₅]₂ were likewise prepared from the phosphines and excess [Mo(CO)₅(THF)]

New ferrocene-derived hydroxymethylphosphines: FcP(CH₂OH)₂ [Fc=(η⁵-C₅H₅)Fe(η⁵-C₅H₄)] and the dppf analogue 1,1′-Fc′[P(CH₂OH)₂]₂ [Fc′=Fe(η⁵-C₅H₄)₂]

Reactions of the ferrocene-phosphines FcPH₂ and 1,1′-Fc′(PH₂)₂ with excess formaldehyde gives the new hydroxymethylphosphines FcP(CH₂OH)₂ 1 and 1,1′-Fc′[P(CH₂OH)₂]₂ 2, respectively. Phosphine 1 is an air-stable crystalline solid, whereas 2 is isolated as an oil. Reaction of 1 with H₂O₂, S₈ or Se gives the chalcogenide derivatives FcP(E)(CH₂OH)₂ (E=O, S or Se), whilst reaction of 2 with S8 gives 1,1′-Fc′[P(S)(CH₂OH)₂]₂, which were fully characterised. Phosphine 1 was also characterised by an X-ray crystal structure determination

Synthesis and characterisation of ferrocenyl-phosphonic and -arsonic

The ferrocene-derived acids FcCH₂CH₂E(O)(OH)₂ [4, E=P; 10, E=As; Fc=Fe(η₅-C₅H₅)(η⁵-C₅H₄)] have been synthesized by the reaction of FcCH₂CH₂Br with either P(OEt)₃ followed by hydrolysis, or with sodium arsenite followed by acidification. Reaction of FcCH₂OH with (EtO)₂P(O)Na gave FcP(O)(OEt)(OH), which was converted to FcCH₂P(O)(OH)₂ (3) by silyl ester hydrolysis using Me₃SiBr–Et₃N followed by aqueous work-up. Similarly, the known phosphonic acid FcP(O)(OH)₂and the new derivatives 1,1′-Fc′[P(O)(OH)₂]₂ [Fc′=Fe(η⁵-C₅H₄)₂] and 1,1′-Fc′[CH₂P(O)(OH)₂]₂(7) have been synthesized via their corresponding esters. X-ray crystal structure determinations have been carried out on 3 and 7, and the hydrogen-bonding networks discussed. Electrospray mass spectrometry has been employed in the characterization of the various acids. Phosphonic acids give the expected [M–H]− ions and their fragmentation at elevated cone voltages has been found to be dependent on the acid. FcP(O)(OH)₂ fragments to [C₅H₄PO₂H]−, but in contrast Fc(CH₂)nP(O)(OH)₂ (n=1, 2) give Fe{η⁵-C₅H₄(CH₂)nP(O)O₂]− ions, which are proposed to have an intramolecular interaction between the Fe atom and the phosphonate group. In contrast, arsonic acid (10), together with PhAs(O)(OH)₂for comparison, undergo facile alkylation (in methanol or ethanol solvent), and at elevated cone voltages (e.g. >60 V) undergo carbon–arsenic bond cleavage giving [CpFeAs(O)(OR)O]− (R=H, Me, Et) and ultimately [AsO₂]− ions

Performance and Competence of Learning Disabled and High-Achieving High School Students on Essential Cognitive Skills

This research was published by the KU Center for Research on Learning, formerly known as the University of Kansas Institute for Research in Learning Disabilities.This study was designed to measure performance differences of learning disabled and high-achieving high school students judged crucial to academic learning and to determine teacher performance standards on those same crucial learning skills, Results showed that high achievers performed significantly batter than LD students across the complex, and within every domain, of learning skills assessed. In addition, significantly greater proportions of LD students fall below teacher-derived standards of minimal competence in all skill areas assessed than do high-achieving students

Desert springs: deep phylogeographic structure in an ancient endemic crustacean (Phreatomerus latipes)

Extent: 13p.Desert mound springs of the Great Artesian Basin in central Australia maintain an endemic fauna that have historically been considered ubiquitous throughout all of the springs. Recent studies, however, have shown that several endemic invertebrate species are genetically highly structured and contain previously unrecognised species, suggesting that individuals may be geographically ‘stranded in desert islands’. Here we further tested the generality of this hypothesis by conducting genetic analyses of the obligate aquatic phreatoicid isopod Phreatomerus latipes. Phylogenetic and phylogeographic relationships amongst P. latipes individuals were examined using a multilocus approach comprising allozymes and mtDNA sequence data. From the Lake Eyre region in South Australia we collected data for 476 individuals from 69 springs for the mtDNA gene COI; in addition, allozyme electrophoresis was conducted on 331 individuals from 19 sites for 25 putative loci. Phylogenetic and population genetic analyses showed three major clades in both allozyme and mtDNA data, with a further nine mtDNA sub-clades, largely supported by the allozymes. Generally, each of these sub-clades was concordant with a traditional geographic grouping known as spring complexes. We observed a coalescent time between ~ 2–15 million years ago for haplotypes within each of the nine mtDNA sub-clades, whilst an older total time to coalescence (>15 mya) was observed for the three major clades. Overall we observed that multiple layers of phylogeographic history are exemplified by Phreatomerus, suggesting that major climate events and their impact on the landscape have shaped the observed high levels of diversity and endemism. Our results show that this genus reflects a diverse fauna that existed during the early Miocene and appears to have been regionally restricted. Subsequent aridification events have led to substantial contraction of the original habitat, possibly over repeated Pleistocene ice age cycles, with P. latipes populations becoming restricted in the distribution to desert springs.Michelle T. Guzik, Mark A. Adams, Nicholas P. Murphy, Steven J.B. Cooper and Andrew D. Austi

NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods

Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submit- Avenue, Silver Spring, Maryland 20993; 22Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia; 23Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovacˇ ic´ a 1, 10 000 Zagreb, Croatia; 24Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303; 25glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany; 26Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada; 27Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739–8530 Japan; 28ImmunoGen, 830 Winter Street, Waltham, Massachusetts 02451; 29Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31–126 Krakow, Poland; 30Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287; 31Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704; 32Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363–883 Korea (South); 33Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363–700, Korea (South); 34Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands; 35Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom; 36Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia; 37Proteomics, Central European Institute for Technology, Masaryk University, Kamenice 5, A26, 625 00 BRNO, Czech Republic; 38Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany; 39Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany; 40AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom; 41Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033; 42Analytical R&D, MilliporeSigma, 2909 Laclede Ave. St. Louis, Missouri 63103; 43MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108; 44MSD, Molenstraat 110, 5342 CC Oss, The Netherlands; 45Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, 5–1 Higashiyama, Myodaiji, Okazaki 444–8787 Japan; 46Graduate School of Pharmaceutical Sciences, Nagoya City University, 3–1 Tanabe-dori, Mizuhoku, Nagoya 467–8603 Japan; 47Medical & Biological Laboratories Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464–0858 Japan; 48National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom; 49Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158–8501 Japan; 50New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938; 51New York University, 100 Washington Square East New York City, New York 10003; 52Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom; 53GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland; 54Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695; 55Pantheon, 201 College Road East Princeton, New Jersey 08540; 56Pfizer Inc., 1 Burtt Road Andover, Massachusetts 01810; 57Proteodynamics, ZI La Varenne 20–22 rue Henri et Gilberte Goudier 63200 RIOM, France; 58ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545; 59Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan; 60Children’s GMP LLC, St. Jude Children’s Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105; 61Sumitomo Bakelite Co., Ltd., 1–5 Muromati 1-Chome, Nishiku, Kobe, 651–2241 Japan; 62Synthon Biopharmaceuticals, Microweg 22 P.O. Box 7071, 6503 GN Nijmegen, The Netherlands; 63Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139; 64Department of Chemistry and Biochemistry, Texas Tech University, 2500 Broadway, Lubbock, Texas 79409; 65Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085; 66United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India; 67Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 68Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 69Department of Chemistry, University of California, One Shields Ave, Davis, California 95616; 70Horva´ th Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary; 71Translational Glycomics Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Egyetem ut 10, Hungary; 72Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711; 73Proteomics Core Facility, University of Gothenburg, Medicinaregatan 1G SE 41390 Gothenburg, Sweden; 74Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden; 75Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden; 76Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany; 77Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2; 78Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France; 79Natural and Medical Sciences Institute, University of Tu¨ bingen, Markwiesenstrae 55, 72770 Reutlingen, Germany; 80Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; 81Division of Bioanalytical Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands; 82Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757; 83Zoetis, 333 Portage St. Kalamazoo, Michigan 49007 Author’s Choice—Final version open access under the terms of the Creative Commons CC-BY license. Received July 24, 2019, and in revised form, August 26, 2019 Published, MCP Papers in Press, October 7, 2019, DOI 10.1074/mcp.RA119.001677 ER: NISTmAb Glycosylation Interlaboratory Study 12 Molecular & Cellular Proteomics 19.1 Downloaded from https://www.mcponline.org by guest on January 20, 2020 ted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide communityderived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods. Molecular & Cellular Proteomics 19: 11–30, 2020. DOI: 10.1074/mcp.RA119.001677.L

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival